Journal
STEM CELLS AND DEVELOPMENT
Volume 27, Issue 20, Pages 1406-1411Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/scd.2017.0304
Keywords
adipose-derived mesenchymal stem cells; chronic kidney disease; renal fibrosis; cell therapy
Funding
- National Natural Science Foundation of China [81270769]
- Jiangsu Provincial Natural Science Foundation [BK20161172]
- Qing Lan'' of Jiangsu Province
- Jiangsu Provincial Commission of Health and Family Planning [H201628]
- Liu Ge Yi'' of Jiangsu Province
- seventh Liu Da Ren Cai Gao Feng'' of Jiangsu Province, China [2010-WS043]
- Technology Development Foundation of Kuitun City [201134]
- Jiangsu Overseas and Training Program for University Prominent Young and Middle-aged Teachers and Presidents
- shi er wu ke jiao xing wei'' Key Medical Personnel of Jiangsu Province [RC2011116]
Ask authors/readers for more resources
As chronic kidney disease progresses, kidney tissue inevitably undergoes cell loss, accumulation of extracellular matrix, and kidney tissue fibrosis, eventually leading to end-stage renal disease. With the continuous innovation of cell therapy technology, mesenchymal stem cells are used in numerous fields, including cardiovascular diseases, diabetes, and kidney tissue injury repair. Adipose-derived mesenchymal stem cells (AMSCs), a type of pluripotent stem cells, have the potential for self-renewal and proliferation with low immunogenicity and significant anti-inflammatory properties. AMSCs can promote impaired cell regeneration and remodeling in renal lesions, thus avoiding further worsening of renal disease and even blocking or reversing the process of renal fibrosis. In this review, we discuss the mechanisms involved in the treatment of renal fibrosis with AMSCs and summarize the potential hazards that may exist in cell therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available